Radioactive tracer could reveal breast Cancer's inner workings

NCT ID NCT02284919

Ongoing Diagnosis Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a new radioactive tracer called [18F]ISO-1 in PET scans for people with breast cancer. The tracer targets sigma-2 receptors, which are linked to how fast cancer cells multiply. Researchers want to see if the scan can measure tumor growth rates and help guide treatment decisions. The study involves 30 adults with known or suspected breast cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [18F]ISO-1, a radioactive tracer used in PET scans
What this could lead to: If successful, this could lead to a new imaging method to better detect breast cancer and measure how fast tumors are growing without needing a biopsy.
What could go wrong: This is an early phase 1 study with only 30 participants, so the tracer may not reliably distinguish cancer from normal tissue or may have safety issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST NEOPLASM

Contacts and locations

Locations

University of Pennsylvania Hospital

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.